Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | ataxin 2 | Starlite/ChEMBL | No references |
Homo sapiens | lamin A/C | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | musashi | 0.0033 | 1 | 0.5 |
Loa Loa (eye worm) | intermediate filament protein | 0.0033 | 1 | 1 |
Echinococcus granulosus | intermediate filament protein | 0.0033 | 1 | 0.5 |
Schistosoma mansoni | intermediate filament proteins | 0.0033 | 1 | 0.5 |
Echinococcus granulosus | lamin | 0.0033 | 1 | 0.5 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.003 | 0.8593 | 0.5 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0.8593 | 0.5 |
Onchocerca volvulus | 0.0033 | 1 | 0.5 | |
Brugia malayi | hypothetical protein | 0.002 | 0.1458 | 0.1458 |
Brugia malayi | hypothetical protein | 0.003 | 0.8593 | 0.8593 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.8593 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0033 | 1 | 1 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.003 | 0.8593 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.003 | 0.8593 | 0.5 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.8593 | 0.5 |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0033 | 1 | 1 |
Schistosoma mansoni | lamin | 0.0033 | 1 | 0.5 |
Echinococcus granulosus | lamin dm0 | 0.0033 | 1 | 0.5 |
Echinococcus multilocularis | lamin | 0.0033 | 1 | 0.5 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0.8593 | 0.5 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.003 | 0.8593 | 0.5 |
Onchocerca volvulus | 0.0033 | 1 | 0.5 | |
Loa Loa (eye worm) | hypothetical protein | 0.0032 | 0.9606 | 0.9606 |
Schistosoma mansoni | lamin | 0.0033 | 1 | 0.5 |
Brugia malayi | Intermediate filament tail domain containing protein | 0.0033 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.003 | 0.8593 | 0.8593 |
Echinococcus multilocularis | lamin dm0 | 0.0033 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 9.285 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 12.5893 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 13.1154 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 19.9526 um | PUBCHEM_BIOASSAY: qHTS Assay for Modulators of Lamin A Splicing. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 20.5962 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (functional) | = 22.3872 um | PUBCHEM_BIOASSAY: qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP). (Class of assay: confirmatory) [Related pubchem assays: 1482, 1471 ] | ChEMBL. | No reference |
Potency (functional) | 23.9341 uM | PUBCHEM_BIOASSAY: qHTS profiling assay for firefly luciferase inhibitor/activator using purified enzyme and Km concentrations of substrates (counterscreen for miR-21 project). (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID2288, AID2289, AID2598, AID411] | ChEMBL. | No reference |
Potency (functional) | 25.929 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 25.929 uM | PubChem BioAssay. qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PubChem BioAssay. qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PubChem BioAssay. qHTS Assay for Activators of ClpP. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Human Jumonji Domain Containing 2E (JMJD2E). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (binding) | = 50.1187 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.